AlphAIAlphAI — Financial news for AI agents
tradingview.com

InMed Pharmaceuticals Inc. (MWG) Expects Merger Close Nov. 6; MTRI Trading Nov. 9

InMed Pharmaceuticals (MWG) anticipates completing its merger with Mentari Therapeutics on Nov. 6. Trading under the new name and ticker MTRI is expected to start Nov. 9, pending final conditions.

Original reporting
tradingview.com
Published Nov 5, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
InMed Pharmaceuticals Inc. (MWG) Expects Merger Close Nov. 6; MTRI Trading Nov. 9 — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

Provides traders with a clear timeline to act on the merger, reducing uncertainty and enabling positioning ahead of the close.

02

Market read

Primary M&A update with concrete dates, relevant for short‑term traders and sector analysts.

03

What to watch

Potential integration challenges and dilution effects on existing shareholders.

Relevance 7/10Novelty 7/10Timing: pre‑market before Nov 6 close

Background

The article reports a near‑term milestone for the InMed‑Mentari merger, confirming expected dates for closing and new ticker launch.

Market effects

Sector

Consolidates the biotech/therapeutics sector, potentially prompting re‑rating of peers.

Regional

Adds to activity on the TSX biotech segment.

Global

Limited to investors tracking North American biotech M&A.

Counterpoint

What could challenge this read

If regulatory or financing hurdles arise, the merger could be delayed, causing downside.

Key entities

  • company
    InMed Pharmaceuticals Inc.

    Canadian biotech firm merging with Mentari Therapeutics.

  • company
    Mentari Therapeutics Inc.

    Biotech company that will trade under MTRI after merger.

Read at source← All news

Also covered by

3 outlets

Related articles

$INMHighAI 9/10

Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing

InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing Mentari is advancing a robust pipeline of biologics for the prevention of migraine, including MT-001 and MT-002, which target clinically valida

SEC EDGAR 8-K
HighAI 8/10

InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics

InMed Pharmaceuticals, now renamed Mentari Therapeutics (NASDAQ: INM), completed its merger with privately held Mentari Therapeutics. The combined company will trade on Nasdaq under the ticker 'MTRI' starting November 9, 2026. Pre-merger Mentari raised $490 million in private financings. The company focuses on migraine therapies, with lead programs MT-001 and MT-002.

prnewswire.com
$INMMed

InMed Pharmaceuticals: InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"

InMed Pharmaceuticals (INM) expects to complete its merger with Mentari Therapeutics on November 6, 2026, and begin trading on Nasdaq as Mentari Therapeutics (MTRI) on November 9, 2026. The company will redomesticate from Canada to Nevada. Shareholders may receive contingent value rights, but those who buy shares on November 5, 2026, will not qualify.

finanznachrichten.de
$INMMed

InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation

InMed Pharmaceuticals Inc. (INM) filed an SEC Form 8-K — Regulation FD Disclosure. NASDAQ: INM 1800 - 510 West Georgia St. Vancouver, BC, Canada V6B 0M3 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation V

SEC EDGAR 8-K